title: Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.
abstract: CP-122,721 [(+)-(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2 -phenylpiperidine] interacts with high affinity (pIC50 = 9.8) at the human NK1 receptor expressed in IM-9 cells. In the presence of CP-122,721, there was a reduction in Bmax of [125I]BH-SP binding with no change in affinity suggesting that CP-122,721 does not interact with the NK1 receptor in competitive manner. In an in vitro functional assay. CP-122,721 blocked SP-induced excitation of locus ceruleus cells in guinea pig brain slices with a IC50 value of 7 nM. In vivo, CP-122,721 potently blocked plasma extravasation in guinea pig lung elicited by aerosolized capsaicin (1 mM) with an ID50 = 0.01 mg/kg, p.o. Orally administered CP-122,721 antagonized Sar9, Met (O2)11-SP-induced locomotor activity in guinea pigs with an ID50 = 0.2 mg/kg suggesting good entry into the central nervous system. In addition, consistent with insurmountable blockade observed in vitro, CP-122,721 (0.01, 0.03 0.3 mg/kg, p.o.) produced a rightward shift in the dose response curve for SP-induced hypotension in the awake dog that was accompanied by a decrease in the maximal response. Thus, in vitro and in vivo CP-122,721 appears to behave functionally as a non-competitive antagonist producing an insurmountable blockade of the actions of SP.
authors.affiliation: Department of Neuroscience, Pfizer Inc., Groton, CT 06340, USA.
authors.forename: S
authors.initials: S
authors.lastname: McLean
authors.forename: A
authors.initials: A
authors.lastname: Ganong
authors.forename: P A
authors.initials: PA
authors.lastname: Seymour
authors.forename: D K
authors.initials: DK
authors.lastname: Bryce
authors.forename: R T
authors.initials: RT
authors.lastname: Crawford
authors.forename: J
authors.initials: J
authors.lastname: Morrone
authors.forename: L S
authors.initials: LS
authors.lastname: Reynolds
authors.forename: A W
authors.initials: AW
authors.lastname: Schmidt
authors.forename: S
authors.initials: S
authors.lastname: Zorn
authors.forename: J
authors.initials: J
authors.lastname: Watson
authors.forename: A
authors.initials: A
authors.lastname: Fossa
authors.forename: M
authors.initials: M
authors.lastname: DePasquale
authors.forename: T
authors.initials: T
authors.lastname: Rosen
authors.forename: A
authors.initials: A
authors.lastname: Nagahisa
authors.forename: M
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: J
authors.initials: J
authors.lastname: Heym
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008125:Locus Coeruleus / Q000187:drug effects; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D012472:Salivation; D013373:Substance P / Q000037:antagonists & inhibitors
chemical_list: D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D018040:Receptors, Neurokinin-1; D013373:Substance P; C099414:(2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine